With the in vitro evidence in human U251 cells that treatment of tumor cells with GSK126 and IFNγ increased T cell chemoattraction, we evaluated the in vivo impact of treating immunocompetent tumor bearing mice with the drug, GSK126 in combination with an ICI, anti-PD-1 currently under investigation to treat patients with GBM by measuring the effects on tumor growth and survival. The gene discussed is IFNG; the disease is neoplasm.